Rivastigmine decreases brain damage in HIV patients with mild cognitive deficits

Rivastigmine has been shown to improve cognition in HIV+ patients with minor neurocognitive disorders; however, the mechanisms underlying such beneficial effect are currently unknown. To assess whether rivastigmine therapy is associated with decreased brain inflammation and damage, we performed T1/T...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ann Clin Transl Neurol
Hlavní autoři: Perrotta, Gaetano, Bonnier, Guillaume, Meskaldji, Djalel‐Eddine, Romascano, David, Aydarkhanov, Ruslan, Daducci, Alessandro, Simioni, Samanta, Cavassini, Matthias, Metral, Melanie, Lazeyras, François, Meuli, Reto, Krueger, Gunnar, Du Pasquier, Renaud A., Granziera, Cristina
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2017
Témata:
Brief Communications
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5740253/
https://ncbi.nlm.nih.gov/pubmed/29296621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acn3.493
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky